Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 495

Similar articles for PubMed (Select 16754936)

1.

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA.

J Clin Oncol. 2006 Jul 1;24(19):3113-20. Epub 2006 Jun 5.

2.

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.

Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San Miguel J.

Br J Haematol. 2009 Mar;144(6):895-903. doi: 10.1111/j.1365-2141.2008.07573.x. Epub 2009 Jan 16.

PMID:
19170677
3.

Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.

Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG.

Cancer. 2007 Sep 1;110(5):1042-9. Review.

4.

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.

Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA.

J Clin Oncol. 2009 Jul 20;27(21):3518-25. doi: 10.1200/JCO.2008.18.3087. Epub 2009 Jun 15.

5.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC.

N Engl J Med. 2003 Jun 26;348(26):2609-17.

6.

Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity.

Lanzani F, Mattavelli L, Frigeni B, Rossini F, Cammarota S, Petrò D, Jann S, Cavaletti G.

J Peripher Nerv Syst. 2008 Dec;13(4):267-74. doi: 10.1111/j.1529-8027.2008.00192.x.

PMID:
19192066
7.

Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.

Dubois D, Dhawan R, van de Velde H, Esseltine D, Gupta S, Viala M, de la Loge C.

J Clin Oncol. 2006 Feb 20;24(6):976-82. Epub 2006 Jan 23.

8.

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.

Corso A, Mangiacavalli S, Varettoni M, Pascutto C, Zappasodi P, Lazzarino M.

Leuk Res. 2010 Apr;34(4):471-4. doi: 10.1016/j.leukres.2009.07.022. Epub 2009 Aug 11.

PMID:
19674790
9.

Safety and efficacy results from an international expanded access programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients.

Quach H, Horvath N, Cannell P, Mikhael JR, Butcher BE, Prince HM.

Intern Med J. 2009 May;39(5):290-5. doi: 10.1111/j.1445-5994.2008.01738.x. Epub 2008 Jun 28.

PMID:
19371392
10.

A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma.

Bao T, Goloubeva O, Pelser C, Porter N, Primrose J, Hester L, Sadowska M, Lapidus R, Medeiros M, Lao L, Dorsey SG, Badros AZ.

Integr Cancer Ther. 2014 Sep;13(5):396-404. doi: 10.1177/1534735414534729. Epub 2014 May 26.

PMID:
24867959
11.

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.

Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K.

Cancer. 2005 Nov 15;104(10):2141-8.

12.

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.

Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, Orlowski RZ, Richardson PG, Anderson J, Nix D, Esseltine DL, Anderson KC; SUMMIT/CREST Investigators.

Cancer. 2005 Mar 15;103(6):1195-200.

13.

A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression.

Ohguchi H, Sugawara T, Ishikawa I, Okuda M, Tomiya Y, Yamamoto J, Onishi Y, Fujiwara Yamada M, Ishizawa K, Kameoka J, Harigae H.

Int J Hematol. 2009 Apr;89(3):342-7. doi: 10.1007/s12185-009-0279-4. Epub 2009 Mar 19.

PMID:
19296199
14.

Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, Wright JJ, Powers J, Walsh W, Eisenhauer E; National Cancer Institute of Canada Clinical Trials Group.

J Clin Oncol. 2007 Apr 20;25(12):1570-5. Epub 2007 Mar 12.

15.

Optimizing bortezomib treatment in patients with relapsed multiple myeloma.

Richardson P.

Clin Adv Hematol Oncol. 2006 May;4(5):4-5; discussion 8; suppl 13. No abstract available.

PMID:
16832859
16.

Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.

Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel JF, Crawford B, Massaro J, Dhawan R, Gupta S, Anderson KC.

Br J Haematol. 2008 Nov;143(4):511-9. doi: 10.1111/j.1365-2141.2008.07378.x.

PMID:
18986387
17.

Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, Purner M, Lee SP, Wilson J, Morrison B, Adams J, Schenkein D, Swift R.

J Clin Oncol. 2006 Feb 20;24(6):937-44. Epub 2006 Jan 17.

18.

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL, Goy A.

J Clin Oncol. 2006 Oct 20;24(30):4867-74. Epub 2006 Sep 25.

19.

Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients.

Velasco R, Petit J, Clapés V, Verdú E, Navarro X, Bruna J.

J Peripher Nerv Syst. 2010 Mar;15(1):17-25. doi: 10.1111/j.1529-8027.2010.00248.x.

PMID:
20433602
20.

Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.

Hainsworth JD, Spigel DR, Barton J, Farley C, Schreeder M, Hon J, Greco FA.

Cancer. 2008 Aug 15;113(4):765-71. doi: 10.1002/cncr.23606.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk